Listen to a soundcast of the January 26, 2023, FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for non-small cell lung cancer

Listen to a soundcast of the January 26, 2023, FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for non-small cell lung cancer

Listen to a soundcast of the January 26, 2023, FDA approval of Keytruda (pembrolizumab)&nbsp;as&nbsp;adjuvant treatment for non-small cell lung cancer

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for non-small cell lung cancer

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Share FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for non-small cell lung cancer

Sign up to save your podcasts

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for non-small cell lung cancer

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for non-small cell lung cancer